1. ¹Division of Clinical Immunology, Karolinska Institute, Karolinska University Hospital at Huddinge, Stockholm and
2. ²Department of Surgery, Sahlgrenska University Hospital, Göteborg, Sweden

Correspondence: Michael E Breimer, Department of Surgery, Sahlgrenska University Hospital, S-413 45 Göteborg, Sweden. Email: michael.breimer@clinchem.gu.se

Received 29 April 2005; Accepted 4 May 2005; Published online 21 October 2005.

Abstract

The relative shortage of human organs for transplantation is today the major barrier to a broader use of transplantation as a means of treating patients with end-stage organ failure. This barrier could be partly overcome by an increased use of blood group ABO-incompatible live donors, and such trials are currently underway at several transplant centres. If xenotransplantation can be used clinically in the future, the human organ shortage will, in principle, be eradicated. In both these cases, carbohydrate antigens and the corresponding anti-carbohydrate antibodies are the major primary immunological barriers to overcome. Refined carbohydrate-based therapeutics may permit an increased number of ABO-incompatible transplantations to be carried out, and may remove the initial barriers to clinical xenotransplantation. Here, we will discuss the chemical characteristics of protein–carbohydrate interactions and outline carbohydrate-based antirejection therapies as used today in experimental as well as in clinical settings. Novel mucin-based adsorbers of natural anti-carbohydrate antibodies will also be described.